20n Bio

20n Bio, a biotech startup invested by venture capital and registered in September 2021, is located in Hangzhou. 20n Bio is committed to using artificial intelligence to assist in the development of novel protein drugs to address unmet clinical needs. The company's core technology platform combines advanced algorithms with high-throughput wet lab techniques to design and screen proteins that meet physicochemical, functional, and pharmacological requirements, targeting undruggable small-molecule targets. Starting with its technology platform, the company is actively advancing pipeline development for cancer and other genetic diseases. Its research and development center is located in Philadelphia, USA.